Olivier Elemento, PhD
Bishoy M. Faltas, MD
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Research Officer of EIPM effective immediately. EIPM is a large multidisciplinary institute that uses precision medicine technologies and informatics to uncover the molecular mechanisms of disease and individualize disease treatment and prevention. In this new capacity, Dr. Faltas will oversee EIPM’s strategic research directions, and develop new programs and partnerships that integrate biology, technology, and clinical advances to revolutionize patient care.
Dr. Faltas is the Gellert Family–John P. Leonard, MD, Research Scholar in Hematology and Medical Oncology; Associate Professor of Medicine and of Cell and Developmental Biology; and a practicing oncologist who specializes in bladder cancer at NewYork–Presbyterian/Weill Cornell Medical Center. Previously serving as Director of Bladder Cancer Research for EIPM, Dr. Faltas will continue his duties in this role in addition to his new responsibilities as Chief Research Officer. Dr. Faltas’ responsibilities will include leading new faculty recruitment efforts in the basic and translational sciences at EIPM.
Genomic Medicine and Precision Health
The Faltas Laboratory is dedicated to studying bladder cancer as a model disease for dissecting the fundamental biological mechanisms that drive the evolution of human cancers.
Dr. Elemento shared these comments: “This appointment comes at a time when EIPM is poised for groundbreaking advancements in genomic medicine and precision health. Our growth has been bolstered recently by a transformational institutional gift from Israel Englander and plans to open new medical research space in New York, New York.” Dr. Faltas replid: “I am excited to take on this role at the EIPM at such a transformative moment. It is an exciting time in biomedical research and at EIPM. We are now at a point where we can fuse biological insights, clinical advances, and technology to begin to achieve true precision medicine. The potential to impact patient care positively through precision medicine and artificial intelligence is immense. I am looking forward to building new collaborations with our partners to move the needle on what is possible in biomedical research and patient care at Weill Cornell Medicine.”
